InnoCare to Host 2023 Interim Results Webcast on Aug. 30, 2023

BEIJING, August 23, 2023 - InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company will host a webcast to discuss the 2023 interim results and provide a corporate update at 9:30 a.m. and 8:00 p.m. Beijing time on August 30, 2023 respectively. Before the call, the Company will announce the financial results for the first half of the year ended June 30, 2023.

Conference Call Information

InnoCare will host a webcast at 9:30 a.m. Beijing time in Chinese and at 8:00 p.m. Beijing time in English on August 30, 2023. Participants must register in advance of the conference call. Details are as follows:

For Chinese conference call, please register through the below link:

Register below if you are outside Mainland China:

https://morganstanley.webcasts.com/starthere.jsp?ei=1627247&tp_key=647b0cba5d

Register below if you are within Mainland China:

https://morganstanley.cnwebcasts.cn/starthere.jsp?ei=1627247&tp_key=647b0cba5d

For English conference call, please register through the below link:

https://goldmansachs.zoom.us/webinar/register/WN_etw2n2DjSuO19Y2D31yjhg

Please pre-register by clicking the above link at least 24 hours before the call.

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and United States.